Welcome to our dedicated page for Longevity Health SEC filings (Ticker: XAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Longevity Health Holdings, Inc. (XAGE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, transaction documents, and listing-related notices. These filings offer detailed information on Longevity’s focus on human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, as well as its corporate and capital markets activities.
Among the key documents are Form 8-K current reports describing material events, such as merger agreements and amendments with 20/20 BioLabs, Inc. and True Health Inc. (THPlasma), and the subsequent termination of the merger agreement with True Health after the transaction was not consummated by the contractual outside date. These reports outline transaction structures, share consideration formulas, and the conditions required for closing.
Investors can also review a Form 25 filed by Nasdaq Stock Market LLC, which serves as a notification of removal of Longevity Health Holdings, Inc.’s common stock and warrants from listing and registration under Section 12(b) of the Securities Exchange Act of 1934 on the Nasdaq Stock Market. This filing documents the delisting process from Nasdaq.
Through Stock Titan, users can follow Longevity’s 10-K annual reports, 10-Q quarterly reports, and additional 8-Ks as they are filed with the U.S. Securities and Exchange Commission. AI-powered summaries help explain the significance of lengthy filings, highlight key risk factor updates, and surface important details in merger agreements, listing decisions, and financing disclosures. The page also makes it easier to monitor insider and executive-related filings, where available, and to understand how corporate actions affect the company’s structure and shareholders.
Longevity Health Holdings, Inc. reported a change in its Board of Directors. On June 1, 2026, Kathryn Gregory notified the company that she was resigning from the Board, effective at the close of business that same day. The company states that her resignation was not due to any disagreement regarding its operations, policies, or practices, indicating a routine governance change rather than a dispute-driven departure.
Longevity Health Holdings, Inc. filed a prospectus supplement registering 44,382 shares of Common Stock as part of its amended Form S-1 prospectus; the supplement incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. The supplement states common stock trades on the OTC under the symbol XAGE and discloses 2,475,321 shares outstanding as of May 13, 2026. The attached Form 10-Q shows $313,396 in cash, a net loss of $(1,431,713) for the three months ended March 31, 2026, and management’s statement that conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Longevity Health Holdings, Inc. reports Q1 2026 net sales of $391,764 and a net loss of $1,431,713, slightly improved from the prior-year loss. Gross profit was $237,025, with operating expenses of $1,565,517.
Cash was $313,396 with negative working capital of $7,086,369, and management states these conditions raise substantial doubt about the company’s ability to continue as a going concern, absent new financing or acquisitions. The quarter included a $200,000 private placement and a leadership change, with Janakiram Ajjarapu becoming Chairman and CEO. An ongoing lawsuit from Puritan Partners over prior convertible notes continues, and an adverse outcome could materially affect the company’s financial condition.
Longevity Health Holdings, Inc. received a new strategic investor and leader as International Capital Partners LLC, controlled by Janakiram (Ajjarapu) J. Ram, acquired 689,656 shares of common stock at $0.29 per share, for a total of $200,000.24, under a Stock Purchase Agreement.
This stake represents 27.9% of the company’s common stock, based on 2,475,321 shares outstanding as of March 16, 2026. In connection with the purchase, Ajjarapu was appointed Chief Executive Officer, Chairman of the Board, and a Class III director effective March 16, 2026, giving him significant influence over both ownership and management. The agreement also requires the company to file a resale registration statement to cover potential future sales of these shares.
Longevity Health Holdings, Inc. director and Chief Executive Officer Ajjarapu J. Ram reported an indirect open-market purchase of 689,656 shares of Common Stock at $0.29 per share. The shares are held through International Capital Partners LLC, and total indirect holdings reported after the transaction are 689,656 shares. A footnote states that the reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Longevity Health Holdings, Inc. director and Chief Executive Officer J. Ram Ajjarapu filed an initial Form 3 reporting indirect ownership of 689,656 shares of Common Stock of XAGE. These shares are held through International Capital Partners LLC, and he disclaims beneficial ownership except for his pecuniary interest.
Longevity Health Holdings, Inc. files a prospectus supplement registering 44,382 shares of Common Stock as an amendment to its Form S-1 prospectus dated June 5, 2024. The supplement incorporates the Company’s Form 10-K for the fiscal year ended December 31, 2025 and attaches an 8-K.
The Company trades on the OTC market under symbol XAGE; the last reported sale price was $0.39 per share on March 30, 2026. The Form 10-K discloses a closed PIPE on March 16, 2026 raising $200,000 from the sale of 689,656 shares at $0.29 per share, a CEO transition with severance payments of $30,000 per month for 12 months (with conditional extension), and management’s conclusion that substantial doubt exists about the Company’s ability to continue as a going concern.
Longevity Health Holdings, Inc. is a microcap aesthetics company focused on regenerative bio-aesthetic skincare and haircare under the Elevai and Carmell brands, using exosome- and platelet-rich plasma-based formulations sold through physicians, medical spas, distributors, and online channels. The company has paused development of its bone and tissue healing candidates to focus on cosmetics.
In March 2026, it completed a private placement of 689,656 common shares at $0.29 for approximately $200,000 with International Capital Partners LLC and simultaneously transitioned leadership, with former Chairman and CEO Rajiv Shukla departing and Janakiram Ajjarapu becoming Chairman and CEO. Shukla receives $30,000 per month for 12 months, with potential extensions and a contingent $480,000 bonus payment tied to a larger capital raise.
As of June 30, 2025, non-affiliate common stock held a market value of about $3.3 million, and 2,475,321 shares were outstanding as of March 27, 2026. The filing highlights substantial competition in the cosmetics industry, reliance on third-party manufacturing and human-tissue-derived inputs, and significant regulatory exposure, including new obligations under the Modernization of Cosmetic Regulation Act of 2022. Management discloses that substantial additional capital will be needed and acknowledges a conclusion that there is substantial doubt about the company’s ability to continue as a going concern.
Longevity Health Holdings entered into a Common Stock Purchase Agreement with International Capital Partners LLC, selling 689,656 shares of common stock at $0.29 per share for aggregate proceeds of approximately $200,000 in a private placement that closed on March 16, 2026.
In connection with the investment, the Board appointed Janakiram (Ram) Ajjarapu as Chairman and Chief Executive Officer, replacing Rajiv S. Shukla, who stepped down under a mutual agreement and will serve as an advisor. The company plans to register the resale of the purchased shares through a future registration statement.
Under a Separation Agreement, Mr. Shukla will receive $30,000 per month for 12 months, potentially extended to 18 months upon a qualifying change in control, and a $480,000 bonus if the company completes a capital raise of at least $1 million, while his existing equity awards are forfeited.
Longevity Health Holdings, Inc. has terminated its planned acquisition of True Health Inc. and Truehealth Management Group LLC. The companies had entered into a Merger Agreement on July 14, 2025, later amended on November 3, 2025, under which True Health would have become a wholly owned subsidiary of Longevity Health.
Under a provision in the agreement allowing either side to walk away if the deal was not closed by November 30, 2025, Longevity Health delivered a formal termination notice on December 8, 2025 after the merger was not completed by the deadline. No termination fee is payable by either party in connection with ending the agreement, so neither side owes a contractual breakup payment.